Atorvastatin correlates with decreased risk of esophageal cancer: A population-based case-control study from Taiwan

Libyan Journal of Medicine

Volumn 7, Issue 1, 2012, Pages

  Lai, Shih Wei ^a,b   Liao, Kuan Fu ^c,d,e   Lai, Hsueh Chou ^b,f   Muo, Chih Hsin ^b,f   Sung, Fung Chang ^b,f  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

^e CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Atorvastatin; Esophageal cancer; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATORVASTATIN; CYCLOOXYGENASE 2 INHIBITOR; FLUINDOSTATIN; HISTAMINE H2 RECEPTOR ANTAGONIST; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; PROTON PUMP INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

ADULT; ALCOHOLISM; ARTICLE; CANCER RISK; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DRUG USE; ESOPHAGUS CANCER; ESOPHAGUS DISEASE; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POPULATION BASED CASE CONTROL STUDY; RISK ASSESSMENT; TAIWAN; TREATMENT DURATION;

EID: 84866115978     PISSN: 19932820     EISSN: 18196357     Source Type: Journal    
DOI: 10.3402/ljm.v7i0.18830     Document Type: Article

References (20)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-917.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
3. Department of Health. Taiwan: main causes of death in 2010. Available from: http://www.doh.gov.tw [cited February 2012].
4. Pera M, Manterola C, Vidal O, Grande L. Epidemiology of esophageal adenocarcinoma. J Surg Oncol. 2005; 92: 151-9.
5. Falk GW. Risk factors for esophageal cancer development. Surg Oncol Clin N Am. 2009; 18: 469-85.
6. Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: orient to occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol. 2009; 24: 729-35.
7. Kamangar F, Chow WH, Abnet CC, Dawsey SM. Environmental causes of esophageal cancer. Gastroenterol Clin North Am. 2009; 38: 27-57.
8. Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol. 2008; 103: 825-37.
9. Sadaria MR, Reppert AE, Yu JA, Meng X, Fullerton DA, Reece TB, et al. Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells. J Thorac Cardiovasc Surg. 2011; 142: 1152-60.
10. Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology. 2010; 138: 2260-6.
11. Lai SW, Liao KF, Liao CC, Muo CH, Liu CS, Sung FC. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine (Baltimore). 2010; 89: 295-9.
12. Lai SW, Muo CH, Liao KF, Sung FC, Chen PC. Risk of acute pancreatitis in type 2 diabetes and risk reduction on antidiabetic drugs: a population-based cohort study in taiwan. Am J Gastroenterol. 2011; 106: 1697-704.
13. Lai SW, Su LT, Lin CH, Tsai CH, Sung FC, Hsieh DP. Polypharmacy increases the risk of Parkinson's disease in older people in Taiwan: a population-based study. Psychogeriatrics. 2011; 11: 150-6.
14. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a populationbased cohort study. Am J Gastroenterol. 2012; 107: 46-52.
15. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005; 352: 2184-92.
16. Khurana V, Sheth A, Caldito G, Barkin JS. Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas. 2007; 34: 260-5.
17. El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009; 136: 1601-8.
18. Chiu HF, Ho SC, Chang CC, Wu TN, Yang CY. Statins are associated with a reduced risk of gastric cancer: a populationbased case-control study. Am J Gastroenterol. 2011; 106: 2098-103.
19. El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol. 2004; 99: 1877-83.
20. de Jonge PJ, Steyerberg EW, Kuipers EJ, Honkoop P, Wolters LM, Kerkhof M, et al. Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol. 2006; 101: 1421-9.